Estimating the Impact on Survival of Not Receiving CAR T Therapy Despite Being Eligible in Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Patients in Germany

被引：0
|
作者：
Buecklein, Veit L. [1 ]
Ayuk, Francis A. [2 ]
Holderried, Tobias A. W. [3 ]
Mai, Christine [4 ]
Kievit, Bradley [5 ]
Blisset, Rob [5 ]
Doble, Brett [6 ]
Reid, Geoff [6 ]
Reimeir, Laura [7 ]
Bruns, Caroline [7 ]
Vadgama, Sachin [6 ]
机构：
[1] LMU Univ Hosp, Dept Med 3, Munich, Germany
[2] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany
[3] Univ klinikum Bonn UKB, Bonn, Germany
[4] AplusA, Lyon, France
[5] Maple Hlth Grp LLC, New York, NY USA
[6] Gilead Co, Kite, Santa Monica, CA USA
[7] Gilead Sci GmbH, Munich, Germany
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-205589
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5037 / 5038
页数：2
相关论文
共 50 条
  • [21] Management of Canadian Patients (Pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World
    Peters, Anthea
    Nowakowski, Grzegorz S.
    Dabas, Rosy
    Amoloja, Theresa
    Xue, Zhenyi
    Koch, Caroline
    Waltl, Eva E.
    Fleury, Isabelle
    BLOOD, 2022, 140 : 3811 - 3813
  • [22] Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
    Awasthi, Rakesh
    Tam, Constantine S.
    Jaeger, Ulrich
    Jaglowski, Samantha
    Foley, Stephen Ronan
    van Besien, Koen
    Wagner-Johnston, Nina D.
    Kersten, Maria Jose
    Schuster, Stephen J.
    Salles, Gilles
    Maziarz, Richard T.
    Anak, Ozlem
    Pacaud, Lida Bubuteishvili
    Gazi, Lucien
    Waldron, Edward
    Hamilton, Jason
    Pruteanu, Iulian
    Tai, Feng
    Mueller, Karen Thudium
    Waller, Edmund K.
    CANCER RESEARCH, 2018, 78 (13)
  • [23] Salvage therapy R-DAOx in patients with relapsed or refractory diffuse large B-CELL lymphoma
    Mappa, S.
    Rigacci, L.
    Nassi, L.
    Puccini, B.
    Alterini, R.
    Carrai, V.
    Bernardi, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 532 - 532
  • [24] Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Hamadani, Mehdi
    Graham, Christopher N.
    Liao, Laura
    Zhang, Katherine H.
    Strat, Hannah
    Ungar, David
    Ai, Weiyun Z.
    Chen, Lei
    Carlo-Stella, Carmelo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Epcoritamab plus R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)
    Karimi, Yasmin
    Abrisqueta, Pau
    de Vos, Sven
    Nijland, Marcel
    Offner, Fritz
    Osei-Bonsu, Kojo
    Rana, Ali
    Archer, Kimberly G.
    Song, Yaou
    Cordoba, Raul
    Falchi, Lorenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] Real-world outcomes of elderly patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) treated with chimeric antigen receptor T-cell (CAR-T) therapy.
    Fitzgerald, Lindsey
    Kittai, Adam
    Nastoupil, Loretta J.
    Waller, Alexandra
    Jacobson, Caron A.
    Saucier, Anna
    Kamdar, Manali K.
    Spradley, Janet
    Denlinger, Nathan
    Chipman, Jonathan
    Hu, Boyu
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Sustained disease control and correlative analyses in tisagenlecleucel treated relapsed/refractory diffuse large B-Cell lymphoma patients (r/r DLBCL)
    Borchmann, P.
    Bachanova, V.
    Westin, J.
    Tam, C.
    Jaeger, U.
    McGuirk, J.
    Holte, H.
    Waller, E.
    Jaglowski, S.
    Bishop, M.
    Andreadis, C.
    Foley, S. R.
    Fleury, I.
    Teshima, T.
    Mielke, S.
    Salles, G.
    Ho, J.
    Izutsu, K.
    Maziarz, R.
    van Besein, K.
    Kersten, M. J.
    Wagner-Johnston, N.
    Kato, K.
    Corradini, P.
    Han, X.
    Agoulnik, S.
    Chu, J.
    Eldjerou, L.
    Pacaud, L.
    Schuster, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 238 - 238
  • [28] Immunogenicity of tisagenlecleucel in relapsed/ refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients.
    Mueller, Karen Thudium
    Grupp, Stephan A.
    Maude, Shannon L.
    Levine, John E.
    Pulsipher, Michael
    Boyer, Michael W.
    August, Keith Jason
    Myers, Gary Douglas
    Awasthi, Rakesh
    Waldron, Edward K.
    Bubuteishvili-Pacaud, Lida
    Taran, Tanya
    Cota, Mariana
    Tam, Constantine Si Lun
    Jager, Ulrich
    Foley, Ronan
    Borchmann, Peter
    Schuster, Stephen J.
    Waller, Edmund K.
    Laetsch, Theodore Willis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [29] CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Messori, Andrea
    Damuzzo, Vera
    Leonardi, Luca
    Agnoletto, Laura
    Chiumente, Marco
    Mengato, Daniele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (07): : 490 - 491
  • [30] A comparison of sampling methods to select real-world relapsed/refractory (R/R) diffuse large-cell B-cell lymphoma (DLBCL) patients with multiple eligible index dates
    Dillon, Paul
    Surinach, Andy
    Castro, Felipe
    Spielewoy, Nathalie
    Black, James A.
    Shang, Aijing
    Radford, John
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 430 - 430
12345